Bavarian Nordic (OTCMKTS:BVNRY – Get Free Report) posted its quarterly earnings data on Friday. The company reported $0.28 EPS for the quarter, Zacks reports. Bavarian Nordic had a net margin of 24.36% and a return on equity of 11.97%.
Bavarian Nordic Price Performance
Shares of BVNRY traded down $0.11 during midday trading on Friday, hitting $11.68. The stock had a trading volume of 301 shares, compared to its average volume of 3,300. Bavarian Nordic has a 1 year low of $8.67 and a 1 year high of $12.72. The firm has a market cap of $2.78 billion, a PE ratio of 11.80 and a beta of 1.33. The stock’s 50 day moving average is $11.48 and its 200 day moving average is $10.21.
Bavarian Nordic Company Profile
Bavarian Nordic is a Danish biotechnology company that develops, manufactures and markets vaccines for infectious diseases and cancer immunotherapy. Founded in 1994, the company is based in Denmark and serves markets in Europe, North America and other regions. Its best-known vaccine is JYNNEOS, also marketed as IMVANEX in Europe and IMVAMUNE in Canada, for protection against smallpox and mpox. Bavarian Nordic also offers vaccines for diseases including rabies, tick-borne encephalitis, typhoid fever and cholera.
Read More
- Five stocks we like better than Bavarian Nordic
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Bavarian Nordic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bavarian Nordic and related companies with MarketBeat.com's FREE daily email newsletter.
